Molecular Formula | C8H11NO4S2 |
Molar Mass | 249.31 |
Density | 1.48±0.1 g/cm3(Predicted) |
Melting Point | 156-160°C |
Boling Point | 590.4±50.0 °C(Predicted) |
Flash Point | 310.8°C |
Solubility | Acetonitrile (Slightly), DMSO (Slightly), Methanol (Slightly) |
Vapor Presure | 1.82E-15mmHg at 25°C |
Appearance | Solid |
Color | White to Off-White |
Maximum wavelength(λmax) | ['236nm(H2O)(lit.)'] |
Merck | 14,3647 |
pKa | 3.71(at 25℃) |
Storage Condition | Sealed in dry,2-8°C |
Refractive Index | 1.615 |
Physical and Chemical Properties | Melting point 156-160°C |
Use | Used as Expectorant Cough medicine for acute and chronic bronchitis, obstructive emphysema and other diseases |
RTECS | AJ1476200 |
Toxicity | LD50 in mice and rats (g/kg): >10 orally; >3.5 i.v. (Gonella) |
white crystals from ethanol, melting point 15 6-158 °c.
after the reaction of ethyl chloroacetate and sodium sulfide, acidic hydrolysis was carried out in the presence of hydrochloric acid, followed by cyclization in the presence of acetyl chloride to give 3-thioglutaric anhydride. The high cysteine lactone hydrochloride dissolved in Tetrahydrofuran, after neutralized with sodium hydroxide aqueous solution, and 3 thioglutaric anhydride reaction, and sodium hydroxide aqueous solution to adjust the pH to 7~8, that is erdostat.
erdostein was developed by the Italian company Refarmed and Edmond Pharma and was marketed in France under the trade names ediul and Vectrin in 1995 by the companies Pierce Fa-bre medicamide and Pharma 2000( Negma), in 1996, it was listed in Sweden under the trade name Mucofor by Vifor, under the trade name Esteclin by sakside, and in Mexico under the trade name Doflus by G1axo Well-come. Developed by Refarmed and Edmond Pharma, Italy, was first launched in France in 1995. Phlegm dissolving drugs can reduce sputum purulent and adhesion, and improve the inhibited respiratory function. Compared with similar products such as acetylcysteine, carboxy methyl, etc., the product has a good effect on acute and chronic bronchitis, and is more effective in improving some respiratory function parameters. For acute and chronic bronchitis, obstructive emphysema and other diseases Cough, Expectoration.
mouse, rat LD50(g/kg):>10 orally;>3.5 intravenously.